Timely donor lymphocyte infusion (DLI) following the detection of impending molecular relapse may significantly improve ...

Bruton tyrosine kinase inhibitors (BTKis) are a cornerstone of chronic lymphocytic leukemia (CLL) therapy, with newer second-generation agents developed to maintain efficacy while improving ...

In an interview with Targeted Oncology, Sarbajit Mukherjee, MD, gastrointestinal (GI) medical oncologist at Baptist Health ...

Median overall survival differed significantly by race: 36.8 months for Black patients versus 48.4 months for White patients ...

“By dividing and conquering…we’re seeing responses in multiple different subtypes of sarcoma…and moving toward more of an individualized therapy that we try to design for every patient, where we take ...

Subgroup analysis revealed a pronounced effect among patients receiving MAC. In this cohort, 6-month grade 2-4 GFS was 35.7% with placebo vs 60.7% with ustekinumab (OR 2.78 for failure; 80% CI, 1.19-6 ...

Acalabrutinib (Calquence) demonstrated efficacy and tolerability across multiple organs affected by steroid-refractory chronic graft-vs-host disease (cGVHD), according to primary findings from a ...

Nonresponse to bridging therapy and high lymphocyte count were predictive of parkinsonism and nonrelapse mortality (NRM) after treatment with ciltacabtagene autoleucel (cilta-cel; Carvykti) in ...

The FDA has expanded the approval of Hologic’s Aptima human papillomavirus (HPV) assay for clinician-collected primary ...

In patients with metastatic breast cancer (mBC) who progress after first-line treatment of CDK4/6 and aromatase inhibitors ...

In an interview with Targeted Oncology, Sarbajit Mukherjee, MD, GI medical oncologist at Baptist Health Miami Cancer ...

A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need ...